Abstract
A saturated fat meal was given to 10 normal males both before and after pretreatment with UK38,485, a thromboxane synthetase inhibitor (Dazmegrel, Pfizer Central Research, Sandwich, Kent, United Kingdom). Following the fat meal at 2 and 4 hr there was laboratory evidence of platelet activation. Dazmegrel lowered baseline platelet activity and lessened platelet activation following the fat meal. This drug should be investigated further as a potential antithrombotic agent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
